15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Biohaven Ltd, 6 rate it Buy or better, 4 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $9.00 to $30.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $16.10 sits 9% above the current $14.73. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.46 next quarter toward $-1.94 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Moderate Buy
Strong Buy00%
Buy655%
Hold436%
Sell19%
Strong Sell00%
Based on 11 analysts giving stock ratings to Biohaven Ltd.
As of Sep, 6 of 11 firms rate BHVN a Buy (4 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
BHVN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.46
Range $-0.67 – $-0.23 · 6 analysts · -49% YoY
Next period, 6 analysts expect Biohaven Ltd. to earn $-0.46 a share (range $-0.67 – $-0.23), versus $-0.90 a year earlier. Full-year consensus is $-1.97, growing to $-1.94 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 6 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $25.0M, rising to $30.0M next year.
Top analysts covering Biohaven Ltd.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BHVN.
#1
Leonid Timashev
RBC Capital · Rank #33
Buy
$23.00+56.1% to target
Overall win rate
48%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #125
Sell
$11.00-25.3% to target
Overall win rate
46%
+ Follow
#3
Charles Duncan
Cantor Fitzgerald · Rank #234
Buy
No targeton BHVN
Overall win rate
42%
+ Follow
#4
Douglas Tsao
HC Wainwright & Co. · Rank #248
Hold
$10.00-32.1% to target
Overall win rate
35%
+ Follow
#5
Sumant Kulkarni
Canaccord Genuity · Rank #293
Buy
$21.00+42.5% to target
Overall win rate
41%
+ Follow
BHVN stock forecast FAQ
What is BHVN's average 12-month price target?+
The 10 analysts with a live target average $16.10 for Biohaven Ltd. over the next 12 months, ranging from a $30.00 high to a $9.00 low.
Is BHVN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 11 analyst ratings, 6 are Buy or Strong Buy, 4 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for BHVN?+
The Street-high target is $30.00 (TD Cowen), and the Street-low is $9.00 (Bernstein). The average of all 10 active targets is $16.10.
How many Wall Street analysts cover BHVN?+
11 analysts have an active rating on Biohaven Ltd., and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering BHVN?+
Among analysts who currently cover BHVN, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #33). Their current call is Buy with a $23.00 target.
What is Biohaven Ltd.'s projected EPS for next quarter?+
The consensus estimate is $-0.46 per share (range $-0.67 – $-0.23) across 6 analysts. Full-year EPS is projected at $-1.97, rising to $-1.94 the following year.
How much revenue is Biohaven Ltd. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $25.0M, growing to $30.0M next year.
Have analysts been upgrading or downgrading BHVN lately?+
As of Sep, 6 of 11 firms rate BHVN a Buy (4 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BHVN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
